RandyW Posted June 6, 2006 Share Posted June 6, 2006 LONDON, June 5 (Reuters) - GlaxoSmithKline Plc (GSK.L: Quote, Profile, Research) has signed a deal to license in a substantial portfolio of tumour-specific antigens from the international Ludwig Institute for Cancer Research to boost its cancer vaccine portfolio. Financial terms of the deal, announced on Monday, were not disclosed. Tumour-specific antigens are proteins expressed only by tumour cells and, when given in combination with special vaccine adjuvants, they are expected to trigger a specific immune response to eliminate cancer cells. The move to expand access to the institute's antigens follows news at the weekend that an experimental Glaxo vaccine showed promise in a mid-stage trial for preventing a recurrence of lung cancer [iD]. © Reuters 2006. All Rights Reserved. Quote Link to comment Share on other sites More sharing options...
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.